Characterization and clinical outcomes of low hormonal receptor positive / HER2 negative early breast cancer

被引：0
|
作者：
Karnmanee, J. [1 ]
Dajsakdipon, T. [2 ]
Sripaiboonkij, N. [3 ]
Dejthevaporn, T. [2 ]
机构：
[1] Mahidol Univ, Ramathibodi Hosp, Fac Med, Bangkok, Thailand
[2] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Med, Bangkok, Thailand
[3] Mahidol Univ, Ramathibodi Hosp, Fac Med, Ramathibodi Comprehens Canc Ctr, Bangkok, Thailand
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.240
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
299P
引用
收藏
页码：S340 / S340
页数：1
相关论文
共 50 条
  • [1] Utility of oncotype in premenopausal women with hormonal receptor (hr) positive her2 negative early breast cancer
    Cudos, A. Gasol
    Murillo, S. Morales
    Der-Abrain, N. Tuset
    Guzman, D. R. Sanchez
    Villellas, F. Vilardell
    Orillo, E. Morera M.
    Morales, C. Canosa
    Olive, J. Mele
    Cid, L. Arbones
    BREAST, 2023, 68 : S19 - S19
  • [2] Characterization of the tumor microenvironment in patients with hormone receptor positive, HER2 negative early breast cancer
    Kearney, Matthew Ryan
    Vanguri, Rami
    Wang, Qi
    Fenn, Kathleen
    Guo, Hua
    Marks, Douglas
    Hibshoosh, Hanina
    Kalinsky, Kevin M.
    Connolly, Eileen
    CANCER RESEARCH, 2022, 82 (04)
  • [3] The impact of low HER2 expression on clinical significances and outcomes in patients with HER2-negative early breast cancer
    Koi, Y.
    Tajiri, W.
    Kawasaki, J.
    Akiyoshi, S.
    Koga, C.
    Nakamura, Y.
    Taguchi, K.
    Tokunaga, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S311 - S312
  • [4] Impact of hormonal receptor status on prognosis in HER2 positive breast cancer
    Cantini, L.
    Pistelli, M.
    Paesani, M.
    Ballatore, Z.
    Bastianelli, L.
    De Lisa, M. G.
    Santoni, M.
    Pagliacci, A.
    Battelli, N.
    Bracci, R.
    Maccaroni, E.
    Valeri, I.
    Biscotti, T.
    Santinelli, A.
    Berardi, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer
    Irfan Cicin
    Hakan Karagol
    Ufuk Usta
    Atakan Sezer
    Sernaz Uzunoglu
    Rusen Alas-Cosar
    Tarkan Yetisyigit
    Kazim Uygun
    Medical Oncology, 2009, 26 : 335 - 343
  • [6] Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer
    Cicin, Irfan
    Karagol, Hakan
    Usta, Ufuk
    Sezer, Atakan
    Uzunoglu, Sernaz
    Alas-Cosar, Rusen
    Yetisyigit, Tarkan
    Uygun, Kazim
    MEDICAL ONCOLOGY, 2009, 26 (03) : 335 - 343
  • [7] Characteristics, Clinical Differences and Outcomes of Breast Cancer Patients with Negative or Low HER2 Expression
    Rosso, Christopher
    Voutsadakis, Ioannis A.
    CLINICAL BREAST CANCER, 2022, 22 (04) : 391 - 397
  • [8] Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer
    Mattos, Bruna RaphaeliSilva
    Cesca, Marcelle Goldner
    Leite, Luciana de Moura
    Tavares, Monique Celeste
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla AlbinaZanco
    Silva, Erick Figueiredo
    Rocha, Francisca Giselle
    Loose, Simone Klug
    Campos, Fernando AugustoBatista
    Sanches, Solange Moraes
    de Lima, Vladmir ClaudioCordeiro
    Ponde, Noam Falbel
    CANCER RESEARCH, 2021, 81 (04)
  • [9] Survival analysis of HER2 receptor negative and HER2 receptor low breast cancer patients at a Philippine hospital
    Arenos, C. C.
    San Juan, M.
    Lim, S.
    Lominoque, A.
    Reveldez, I.
    Sison-DImaano, A.
    Pangandaman, N.
    Tatoy, V.
    Uy, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S1390 - S1390
  • [10] Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer
    Mengdi Chen
    Weilin Chen
    Deyue Liu
    Weiguo Chen
    Kunwei Shen
    Jiayi Wu
    Li Zhu
    Breast Cancer, 2022, 29 : 844 - 853
12345